ArticleIranian journal of pharmaceutical research : IJPR
Geranyl Acetate Attenuates Para-phenylenediamine-induced Cytotoxicity, DNA Damage, Apoptosis, and Inflammation in HaCaT Keratinocytes.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Characterization of Honey- and Essential Oil-Based Structured Systems for Skin Applications.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As consumer demand for cosmetic products that enhance physical appearance continues to rise, the global oxidative hair dye market is experiencing steady growth. Para-phenylenediamine (PPD), a key ingredient in most oxidative hair dyes, is widely used due to its efficacy and low cost. However, its high chemical reactivity has been consistently linked to adverse effects, including allergic contact dermatitis (ACD), eczema, carcinogenicity, and genotoxicity. Objectives: Given the concerns over the long-term use of conventional therapies such as topical corticosteroids (TCS) and calcineurin inhibitors, this study aimed to identify a plant-derived compound with protective properties in a keratinocyte model of PPD-induced toxicity. Methods: To assess the cytoprotective potential of 14 selected plant metabolites, water-soluble tetrazolium salt-1 (WST-1) and lactate dehydrogenase (LDH) assays were performed. Western blotting and reverse transcription-polymerase chain reaction were used to evaluate the anti-apoptotic, anti-DNA damage, and anti-inflammatory effects of geranyl acetate (GA), the most promising candidate. Results: Among the 14 tested plant metabolites, GA was identified as the most effective compound in mitigating cytotoxicity in HaCaT keratinocytes. Co-treatment with GA significantly attenuated PPD-induced phosphorylation of p53 and MAPK, indicating inhibition of the DNA damage response (DDR) pathway. Further experiments revealed that GA suppressed the upregulation of apoptosis-related proteins [p53 upregulated modulator of apoptosis (PUMA), B-cell lymphoma 2 (BCL-2)-associated X protein (BAX), cytochrome c, and cleaved poly (ADP-ribose) polymerase (PARP)]. Moreover, GA treatment decreased the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and NF-κB p65, thereby downregulating five pro-inflammatory cytokines [interleukin (IL)-1α, IL-1β, IL-6, tumor necrosis factor (TNF)-α, and IL-24] and five chemokines [C-C motif chemokine ligand (CCL) 5/RANTES, CCL20/MIP-3α, CCL26/eotaxin-3, C-X-C motif chemokine ligand (CXCL) 1/GRO-α, and CXCL8/IL-8], confirming its anti-inflammatory efficacy. Conclusions: Collectively, this study suggests GA as a promising plant-derived metabolite with cytoprotective, genoprotective, anti-apoptotic, and anti-inflammatory effects in PPD-stimulated HaCaT cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.